

## China Strategy

# Finding the next multibaggers in China: When “Little” becomes “Giant”

### Every new cycle has new winners

A buy-and-hold, beta-focused strategy in the equity market hasn't been an effective way to monetize China's impressive economic growth: In the past decade, during which nominal GDP averaged 9% per annum, MSCI China/SHCOMP merely returned 0%/3% CAGR vs. 10% by SPX. That said, picking the right themes/sectors in the right cycle has proven to be highly rewarding, as exemplified by the outsized alpha from Commodity Cyclical in the early 2000s, Financials in the late 2000s, and Consumer/TMT stocks in the past decade.

### The recipe for multibaggers in Chinese equities

We examine 134 cases where individual names in the existing MSCI China universe returned at least 10x within a rolling 5-year period over the past 2 decades and note these common traits: 1) high realized growth rates; 2) strong small/mid-cap bias; 3) favorable sector beta; 4) inexpensive starting valuations; and, 5) alignment with top-down policy goals/directions. These five factors have collectively explained almost 100% of the occurrence of these historical multibaggers.

### All stars are aligned: Growing with Chinese “Little Giants”

Chinese “Little Giants” check many of the above boxes: They are emerging companies handpicked by the authorities for explicit policy support. Sectorally, they mostly reside in Cap Goods, (new) Materials, Tech Hardware, and Semi, which are critical to Chinese national security, growth sustainability, and achieving “Common Prosperity”. In terms of market attributes, they are growthy small/mid caps trading at historical-low and below-market valuations (PEG).

### Introducing GS “Little Giants” Portfolio (GSSRCNLG)

Among the +700 listed “Little Giants”, we screen for 40 names with favorable rankings in R&D intensity, management incentive plans, sell-side coverage, and attractive growth/valuation profiles to gain targeted exposure to this compelling story. They have an average market cap/ADT of US\$4.5bn/US\$61mn, trade at 25x fP/E and 0.8x fPEG, and offer 36% 22-24E EPS CAGR. Our back-test shows that the basket has risen 115% since 2020, outperforming MXCN/CSI300 by 146pp/123pp.

#### Kinger Lau, CFA

+852-2978-1224 | kinger.lau@gs.com  
Goldman Sachs (Asia) L.L.C.

#### Timothy Moe, CFA

+65-6889-1199 | timothy.moe@gs.com  
Goldman Sachs (Singapore) Pte

#### Kevin Wang, CFA

+852-2978-2446 | kevin.wang@gs.com  
Goldman Sachs (Asia) L.L.C.


#### Si Fu, Ph.D.

+852-2978-0200 | si.fu@gs.com  
Goldman Sachs (Asia) L.L.C.

## Every new cycle has new winners


- **China's economic achievements have been impressive** since Deng Xiaoping introduced "reform and openness/socialist market economy" in 1978 and made his famous "Southern Tour" in 1992: China has delivered a GDP CAGR of 14% since 1990, become the second largest economy in the world (also 2nd largest in terms of market value for equities and bonds globally), managed to grow its per capita income to US\$12,588 as of 2021 (US\$19,170 in PPP terms), and has the largest asset class in the world in its US\$60tn residential housing market.
- While the aggregate market cap of Chinese stocks (A shares and Offshore listed combined) has also increased 17x since 2000, **the realized equity returns at the headline index level have significantly lagged the strong economic performance**: MSCI China, HSCEI, SHCOMP have only gained 0%, -6%, and 3% CAGR in USD terms (-2% to 6% adding dividends) over the past 10 years during which GDP growth was averaging 9% per annum. The realized market returns have also trailed those from major equity markets globally, with SPX, SXXP, TOPIX, and Emerging Markets (MXEF) generating 14%, 6%, 6% and 2% total returns during the same period despite slower macro growth in their respective home markets.
- In our recent Global Strategy Paper—The Asian Earnings Enigma—we discussed **some potential explanations for the disparity between equity gains and economic growth** in China, notably index composition shifts, shares dilution, and compressing profitability due to various macro and sector specific reasons. At a higher level, the issues around regulation tightening targeting the New Economy, the increasing policy/socioeconomic pivot towards socialism and "Common Prosperity" vs. pure market-driven capitalism, and other structural growth headwinds such as a slowing property market, high systemwide leverage, and aging population are also possible reasons for the lackluster equity returns.
- While a simple buy-and-hold, beta-oriented strategy in the stock market may not be the most efficient way to monetize the strong economic growth (potential) in China, **picking the right themes and sectors in the right cycle has proven to be highly rewarding**, as evidenced by the significant realized alpha from Commodity Cyclical in the early 2000s, Financials in the late 2000s, and Consumer/TMT stocks over the past decade. Dividing the past 2 decades into 4 equal periods based on China's 5-Year Plans, we note that the best-3 performing Industry Groups (GICS level 2) on average gained 275% in each of the 4 cycles, outpacing the worst-3 performing sectors by 311pp and the benchmark by 218pp. In our view, this underscores the importance of embracing active investing (or dynamic tilt for passive investing) in China and proactively shifting investment focuses as the economic and political cycles evolve.

**Exhibit 1: China equity indexes have significantly lagged their global peers in the past decade**




Source: MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 2: Strong fundamental growth hasn't translated into equity gains for Offshore-listed equities...**




Source: MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 3: ...as well as for A shares**



Source: FactSet, Goldman Sachs Global Investment Research

**Exhibit 4: Significant sector composition shifts in the benchmark equity index over the past 2 decades**



Source: MSCI, FactSet, Goldman Sachs Global Investment Research

Exhibit 5: Significant rotation and return disparity across sectors over the past 20 years

MSCI China industry groups annual price return during past policy cycles							
Policy cycles	10th 5YP	11th 5YP	12th 5YP	13th 5YP	14th 5YP	CAGR since	
	2001-2005	2006-2010	2011-2015	2016-2020	2021-now	2001/inception	
MXAPJ	76%	55%	-14%	61%	-32%	4%	
China	29%	127%	-10%	82%	-48%	4%	
MXCN GICS Industry Groups							
Cyclicals	Capital Goods	-4%	71%	-27%	-4%	-22%	0%
	Transportation	172%	69%	-26%	-14%	-23%	4%
	Autos & Components	164%	138%	13%	228%	-51%	12%
	Consumer Durables	38%	54%	-34%	257%	-28%	6%
	Consumer Services	-	-28%	25%	385%	-64%	9%
	Commercial Services	-	-	-	27%	-36%	1%
	Retailing	-	153%	-50%	11%	-59%	0%
	Software & Services	-57%	144%	329%	315%	-73%	8%
	Media & Entertainment	-	-	-	-24%	-52%	-9%
	Tech Hardware	-36%	99%	10%	115%	-60%	1%
	Semiconductors	-	67%	-54%	162%	-39%	-3%
Com m	Energy	299%	140%	-53%	-18%	38%	8%
	Materials	312%	113%	-52%	106%	-28%	9%
Financials	Banks	-	106%	-17%	8%	-22%	2%
	Diversified Financials	-46%	456%	-35%	-34%	-46%	-2%
	Insurance	-	423%	-8%	24%	-51%	7%
	Real Estate	231%	108%	10%	45%	-58%	7%
Defensives	Telecom	-15%	100%	7%	-46%	-28%	-2%
	Food & Beverage	118%	206%	-43%	213%	-36%	10%
	Pharma & Biotech	57%	-26%	16%	170%	-51%	4%
	Utilities	110%	24%	66%	18%	-20%	7%
	Health Care Equip & Svcs	-	-	-16%	105%	-58%	-1%
	Average of Top 3	281%	362%	140%	319%	-1%	10%
	Average of Bottom 3	-46%	-10%	-53%	-35%	-66%	-4%
	Gap	327%	372%	193%	354%	65%	14%

pricing as of Oct 3

Source: MSCI, FactSet, Goldman Sachs Global Investment Research

## The recipe for multibaggers in Chinese equities

Given the highly concentrated and dynamic nature of alpha distribution in China historically, we examine **the success cases in the stock market over a long run** to better understand the necessary conditions for generating excess returns, especially at a time when the challenging global macro backdrop characterized by a worsening growth/inflation trade-off, tightening policy, and elevated geopolitical tensions is weighing on risk assets.


Specifically, we construct a study universe encompassing 134 names that were able to generate at least 10x total returns within a 5-year rolling period (monthly) since 2000 based on the current MSCI China index constituents (721 stocks). On average, it took 47 months for these names to reach the 10x threshold, achieving a total return of 1900% when they hit the peak price levels during their respective 5-year (or shorter) outperformance windows. In a nutshell, we observe the following common features among those multibagger stocks:

- 1. High realized growth rates:** 75% of the multibaggers managed to generate at least 40% revenue or profit growth during their outperformance periods. This reinforces the core investing principle that earnings growth is the fundamental driver of equity returns, and our belief that international investors have a structural preference for Growth over Value in China (and in other developing markets more broadly) when growth opportunities become increasingly scarce across the globe.
- 2. Strong small/mid-cap bias:** Low base effect in most cases should be a favorable condition for stock returns as far as market cap size and profit pool is concerned as it simply implies larger headroom for growth, ceteris paribus. Additionally, the policy emphasis of supporting SMEs in the real economy and capital markets, and the regulatory restrictions regarding anti-trust and monopolistic behaviors should theoretically bode well for small/mid caps over time. However, Size is far from a sufficient condition for strong realized alpha empirically, with less than half of the stocks in the universe embarking on their uptrend with an initial market cap below US\$500mn.
- 3. Favorable sector beta:** As detailed in the 5th edition of our China A Primer, China is probably one of the best markets globally to trade/look for idiosyncratic alpha and inefficiency arbitrage opportunities, reflected by its high intra-market return disparity at both the sector and stock levels, a retail-dominated liquidity setup, and still-limited/developing sell-side research footprint. The potential excess returns from an active sector strategy approach could be significant as our previous analysis shows that picking the “average” stocks (i.e. stocks with median returns) in the “right” sectors (Industry Groups with top-quartile returns) would generate 25/34 pp annual alpha over “outperforming” stocks (stock with top-quartile returns) in the “underperforming” sectors (Industry Groups with bottom-quartile returns) in the offshore/A-share market. Our study reveals that 66% of the multibagger cases took place when their corresponding sectors outperformed in the rolling 5-year (or shorter) periods.

4. **Inexpensive starting valuations:** We note that 40% of the companies in our study universe traded below 10x PE or 1x P/B before they eventually became multibaggers. That said, the explanatory power of “low valuation” seems highly linked to the market valuation cycles as 43% of the multibaggers took off when the market was under significant stress, notably 2002-03, 2008-09, and 2015-16. It suggests to us that valuation level might not be a sufficient condition to call a market bottom nor a reason to derail a bull trend, but it does play an important role in framing risk and reward, and driving excess returns in the long run.
5. **Policy tailwinds:** It is widely accepted/embraced by investors that it is critical to align their portfolio with strategic policy goals and directions in China, especially considering the regulatory shocks since late 2020 which have been mainly responsible for the US\$2tn erosion of market capitalization in the TMT sector since then. As such, we leverage our news-searching tools with a specific focus on articles from State-sponsored media outlets (e.g. Xinhua News, People’s Daily, and China Daily, 2mn in total since 2005) to gauge the cyclical policy orientation at the sector level over time. By mapping the relative strength of policy support per our key-words analysis onto historical sector returns, we observe that the Policy factor has coincided with 75% of the occurrence of multibagger cases since 2005.


While other (unobservable) factors might also be contributors to the strong returns, the above five considerations **have indeed collectively explained almost 100%** (133 out of 134 cases) **of the occurrence of historical multibagger stocks**, with those satisfying multiple conditions generally delivering higher absolute returns/alpha. Among them, Size and Valuations have appeared to be less influential while Growth, Policy, and Sector have been comparatively more dominant factors for the creation of multibaggers.

**Exhibit 6: A very concentrated alpha distribution in Chinese equities**




Source: MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 7: China is still the place to look for organic Growth opportunities**




Source: MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 8: "High growth" is a common feature of multibaggers**




Source: MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 9: Favorable base effect matters for ensuing returns as far as Size is concerned**




Source: MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 10: Small/mid caps have outperformed large caps in the past 15 years, but with significant ups and downs**




Source: MSCI, CSI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 11: Historical multibaggers have been concentrated in Materials, Cap Goods, and F&B**




Source: MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 12: Median stocks in top-quartile Industry Groups have performed significantly better than top-quartile stocks in bottom-quartile Industry Groups**



Source: MSCI, FactSet, Goldman Sachs Global Investment Research


**Exhibit 13: The occurrence of multibaggers is negatively correlated with prevailing stock valuations**



Source: MSCI, FactSet, Goldman Sachs Global Investment Research




**Exhibit 14: Low prevailing market valuations appear a necessary condition for multibaggers**



Source: MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 15: Industry groups with more positive policy mentions from official news tend to outperform those with fewer mentions**



Source: Factiva, MSCI, FactSet, Goldman Sachs Global Investment Research


**Exhibit 16: Our policy support heatmap based on news-searching technique**

MXCN Industry Group policy news # from Chinese official media outlets			2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022		
Cyclicals	Capital Goods	(城市化或基础设施或基建) and (发展或提升或促进或刺激)																				
	Transportation	(交通或运输或物流) and (发展或提升或促进或刺激)																				
	Autos & Components	(轿车或新能源汽车或电动车) and (发展或提升或促进或刺激)																				
	Consumer Durables	(健身或国潮或家电) and (发展或提升或促进或刺激)																				
	Consumer Services	(餐饮或教育) and (发展或提升或促进或刺激)																				
	Commercial Services	(环保或环境保护) and (发展或提升或促进或刺激)																				
	Retailing	(消费或购物或平台经济或电商或网购) and (促进或刺激或支持)																				
	Software & Services	(软件或云计算或物联网) and (发展或提升或促进或刺激)																				
	Media & Entertainment	(娱乐或传媒或游戏或广告) and (发展或提升或促进或刺激或稳定或支持)																				
	Tech Hardware	(科技硬件或电子或信息技术) and (发展或提升或促进或刺激)																				
Comm. utilities	Semiconductors	(半导体或芯片) and (发展或提升或促进或刺激)																				
	Energy	(石油或化工或能源) and (发展或提升或促进或刺激)																				
	Materials	(稀土或采矿或材料) and (发展或提升或促进或刺激)																				
Financials	Banks	(银行或贷款) and (发展或提升或促进或刺激)																				
	Diversified Financials	(证券公司或券商或资本市场或股票) and (发展或提升或促进或刺激)																				
	Insurance	(保险或年金或养老) and (发展或提升或促进或刺激)																				
Defensives	Real Estate	(地产或住房或土地) and (提升或促进或刺激或稳定或支持)																				
	Telecom	(电信或电讯或运营商) and (发展或提升或促进或刺激)																				
	Food & Beverage	(消费或食品或酒) and (发展或提升或促进或刺激)																				
	Pharma & Biotech	(制药或生物科技或医疗) and (发展或提升或促进或刺激)																				
	Utilities	(燃气或输电或水利或市政) and (发展或维护或保障或刺激)																				
Health Care Equip & Svcs	(健康或养老或医保) and (发展或提升或促进或刺激)																					

Note: \*Return based on MSCI China GICS Industry Groups Indices from 2001 to 2021; \*\*Proxied by news search # in key state-owned media including People's Daily, Xinhua.net, etc; for each year, cells with more mentions (vs. past 3Y of the industry group) are colored in green, while cells with fewer mentions (vs. past 3Y of the industry group) are colored in grey; 2022 based on annualized year-to-date numbers.

Source: Factiva, MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 17: The five key common denominators of historical multibaggers in the Chinese equity universe**



Source: MSCI, FactSet, Goldman Sachs Global Investment Research

**Exhibit 18: The 5 conditions have collectively explained the occurrence of almost all 134 multibaggers in China in the past 20 years**

# of criteria met	# of stocks	Average Total Return within 5Y (multiple)
0	1	11x
1	10	15x
2	27	18x
3	70	20x
4	24	24x
5	2	34x
<b>Sum</b>	<b>134</b>	<b>20x</b>

Source: MSCI, FactSet, Goldman Sachs Global Investment Research



## Exhibit 19: 134 names in the existing MSCI China universe had returned more than 10x within 5-year rolling periods over the past 20 years

Multibaggers in MXCN constituents: achieved over 10x total return within 5-year period <sup>^</sup>											
Ticker	Name	Industry Group	Start Date	End Date	Max Total Return within 5Y (multiple)	Ticker	Name	Industry Group	Start Date	End Date	Max Total Return within 5Y (multiple)
NTES.UW	NetEase	Media	Sep-01	Mar-06	152x	285.HK	EYD Electronic	IT	Sep-12	Sep-17	14x
1268.HK	MeiDong Auto	Retailing	Feb-16	Nov-20	58x	2338.HK	Weichai Power	Industrials	Feb-06	Nov-10	14x
2333.HK	Great Wall Motor	Autos	Nov-08	Oct-13	57x	1818.HK	Zhaojin Mining Industry	Materials	Oct-08	Aug-11	14x
VIPS.UN	Vipshop	Retailing	Apr-12	Mar-15	55x	6GNE.LW	BeiGene	Health Care	Jul-16	May-21	14x
316.HK	Orient Overseas (Int)	Transportation	Sep-02	Jul-07	47x	135.HK	KunLun Energy	Utilities	Oct-02	Oct-07	14x
1579.HK	Yihai International	Food Bev	Jan-17	Jan-21	42x	902.HK	Huanceng Power	Utilities	Feb-00	Mar-04	14x
900948.CG	Inner Mongolia Yitai Coal	Energy	Sep-03	Oct-07	42x	603737.CG	SKSHU Paint	Materials	Dec-18	Jun-21	13x
6865.HK	Flat Glass	Semis	Jul-18	Aug-21	40x	3323.HK	National Building Material	Materials	May-06	Oct-07	13x
NIO.UN	NIO	Autos	Oct-19	Jan-21	39x	002192.CS	YOUNGY	Materials	Oct-18	Aug-21	13x
700.HK	Tencent	Media	Jan-05	Dec-09	38x	GDS.UQ	GDS Holdings	IT	May-17	Jan-21	13x
1066.HK	Shandong Weigao Medical	Healthcare Equip	Apr-05	Apr-10	37x	288.HK	Kingdee International	IT	Jun-16	Dec-20	13x
358.HK	Jiangxi Copper	Materials	Oct-02	Sep-07	36x	322.HK	Tingyi	Cons Stpl	Mar-05	Nov-09	13x
688.HK	COLI	Real Estate	Mar-03	Oct-07	34x	300601.CS	Kangtai Shipping	Health Care	May-17	Jul-20	13x
189.HK	Dongyue	Materials	Feb-08	Jun-11	33x	1919.HK	COSCO SHIPPING	Industrials	Oct-05	Oct-07	13x
914.HK	Anhui Conch Cement	Materials	Nov-02	Oct-07	33x	3998.HK	Bosideng International	Cons Disc	May-17	Aug-21	13x
1109.HK	China Resources Land	Real Estate	Apr-03	Oct-07	33x	601633.CG	Great Wall Motor	Cons Disc	Dec-18	Oct-21	13x
2600.HK	Aluminum Corp of China	Materials	Sep-02	Aug-07	32x	002460.CS	Ganfeng Lithium	Materials	Jan-17	Aug-21	13x
2382.HK	Sunny Optical	Tech HW	Sep-11	Aug-16	32x	6185.HK	CanSino Biologics	Health Care	Aug-19	Jun-21	13x
1882.HK	Haitian International Hldgs	Cap Goods	Nov-08	Oct-13	31x	603799.CG	Zhejiang Huayou Cobalt	Materials	Feb-16	Jan-21	13x
2313.HK	Shenzhou Int'l	Cons Dur	Oct-08	May-13	30x	000733.CS	Zhenhua Science & Tech	IT	Dec-18	Jun-22	13x
2899.HK	Zijin Mining	Materials	Aug-04	Oct-07	30x	603806.CG	First Applied Material	IT	Jul-18	Aug-21	12x
200596.CS	Anhui Gujing Distillery	Food Bev	Oct-08	Aug-11	30x	300347.CS	Tigemed Consulting	Health Care	Jan-17	Jun-21	12x
754.HK	Hopson Development	Real Estate	Dec-02	Oct-07	29x	600309.CG	Wanhua Chemical	Materials	Mar-16	Feb-21	12x
300274.CS	Sungrow Power Supply	Cap Goods	Oct-18	Jul-21	29x	2628.HK	China Life Insurance	Financials	Apr-04	Oct-07	12x
DQ.UN	Daqo New Energy	Semis	Apr-17	Feb-21	28x	2269.HK	Wuxi Biologics	Health Care	Jul-17	Jun-21	12x
1211.HK	BYD	Autos	Oct-05	Mar-10	28x	2883.HK	Oilfield Services	Energy	Apr-03	Oct-07	12x
1548.HK	Genscript Biotech	Pharma	Jul-16	Jun-21	27x	603486.CG	Ecovacs Robotics	Cons Disc	Nov-19	Jun-21	12x
601100.CG	Hengli Hydraulic	Cap Goods	Feb-16	Jan-21	27x	148.HK	Kingboard Holdings	IT	Oct-02	Sep-07	12x
600809.CG	Xinghuacun Fen Wine	Food Bev	Feb-16	Dec-20	27x	002326.CS	Zhejiang Yongtai Technology	Materials	Jun-18	Oct-21	12x
300661.CS	SG Micro	Semis	Jul-17	Jul-21	25x	300015.CS	Aier Eye Hospital	Health Care	Mar-17	Jun-21	12x
TAL.UN	TAL Education	Cons Svcs	Jan-13	Sep-17	25x	600436.CG	Tongwei	Cons Stpl	May-17	Aug-21	12x
BIDU.UW	Baidu	Media	Apr-06	Mar-11	24x	3888.HK	Kingsoft	Comm Svcs	Feb-09	Jan-14	12x
2331.HK	Li Ning	Cons Dur	Jul-18	Jun-21	24x	600460.CG	Silan Microelectronics	IT	Jan-17	Jul-21	12x
257.HK	China Everbright Int'l	Comm&Prof Svcs	Apr-03	Oct-07	24x	2020.HK	ANTA	Cons Disc	Jul-16	Jun-21	12x
300014.CS	EVE Energy	Cap Goods	Oct-18	Nov-21	23x	1171.HK	Yanzhou Coal Mining	Energy	Mar-00	Feb-05	12x
002709.CS	Tinci Material	Materials	Oct-18	Oct-21	23x	BILI.UW	Bilibili	Media	Apr-18	Feb-21	12x
371.HK	Beijing Enterprises Water	Utilities	Feb-06	May-08	22x	986.HK	China Taiping Insurance	Insurance	Jul-05	Nov-09	11x
002791.CS	Guangdong Kinlong	Cap Goods	Dec-18	Jul-21	21x	002920.CS	Desay SV Automotive	Autos	Dec-18	Jul-22	11x
2018.HK	AAC Technologies	Tech HW	Nov-08	May-13	20x	988.HK	Xinyi Solar	Semis	Feb-16	Dec-20	11x
3311.HK	China State Construction	Cap Goods	Aug-05	Jul-09	20x	144.HK	China Merchants Port	Transportation	Dec-02	Oct-07	11x
1772.HK	Ganfeng Lithium	Materials	Aug-19	Aug-21	20x	2688.HK	ENN Energy Holdings Limited	Utilities	Oct-02	Sep-07	11x
1030.HK	Seazen Group	Real Estate	Sep-14	Jun-19	20x	2889.HK	Nine Dragons	Materials	Oct-08	Nov-09	11x
1177.HK	Sino Biopharm	Pharma	Dec-00	Jun-05	20x	HTHT.UW	H World Group	Cons Svcs	Jun-13	May-18	11x
1044.HK	Hengan	HH Products	Dec-02	Nov-07	19x	2318.HK	Ping An	Insurance	Jul-04	Sep-07	11x
002176.CG	Jiangxi Special Electric Motor	Cap Goods	May-20	Aug-21	19x	694.HK	Beijing Capital International Airport	Transportation	Oct-02	Sep-07	11x
002371.CS	NAURA Technology	Semis	May-17	Jul-21	19x	1193.HK	China Resources Gas	Utilities	Oct-08	Apr-13	11x
603185.CG	Shangji Automation	Cap Goods	Nov-19	Aug-21	19x	WB.UW	Weibo	Media	Sep-15	Jan-18	11x
002812.CS	Yunnan Energy New Material	Materials	Jan-17	Oct-21	18x	386.HK	China Petroleum & Chemical	Energy	Nov-02	Oct-07	11x
601012.CG	LONGi Green Energy	Semis	Dec-16	Oct-21	18x	3808.HK	Sinotruk Hong Kong	Cap Goods	Jan-16	Jul-20	11x
881.HK	Zhongsheng Group	Retailing	Feb-18	Nov-20	18x	631.HK	Sany Heavy	Cap Goods	Sep-16	Aug-21	11x
2238.HK	Guangzhou Automobile	Autos	Feb-00	Jan-04	18x	ZLAB.UQ	Zai Lab	Pharma	Oct-18	May-21	11x
136.HK	Ruyi Holdings	Media	Mar-20	Feb-21	18x	2669.HK	China Overseas	Real Estate	Feb-16	May-20	11x
600763.CG	Topchoice Medical	Healthcare Equip	Aug-17	Jun-21	18x	1995.HK	Ever Sunshine Lifestyle Services	Real Estate	Jan-19	Jan-21	11x
853.HK	MicroPort Scientific	Healthcare Equip	Feb-16	Jan-21	18x	2357.HK	AviChina	Cap Goods	Dec-05	Oct-10	11x
570.HK	Trad Chi Med	Pharma	Oct-08	May-13	17x	600519.CG	Kweichow Moutai	Food Bev	Jan-16	Dec-20	11x
000799.CS	Jiugui Liquor	Food Bev	Oct-18	Jun-21	17x	300223.CS	Ingenic Semiconductor	Semis	Oct-18	Jul-21	11x
900926.CG	Boosight Software	Software	Feb-00	Jun-01	17x	956.HK	China Suntien Green Energy	Energy	Dec-16	Sep-21	10x
857.HK	PetroChina	Energy	Nov-02	Oct-07	17x	300750.CS	CATL	Cap Goods	Aug-18	Nov-21	10x
002568.CS	Shanghai Bairun Investment	Food Bev	Oct-18	Jun-21	17x	002129.CS	TCL Zhonghuan	Semis	Oct-18	Jun-22	10x
601888.CG	China Tourism Group Duty Free	Retailing	Dec-16	May-21	16x	168.HK	Tsingtao Brewery	Food Bev	May-00	Oct-03	10x
1585.HK	Yadea Group	Autos	Jun-16	Jan-21	16x	002850.CS	Kedai	Autos	Oct-18	Nov-21	10x
300595.CS	Ovetek China	Healthcare Equip	Jul-17	Jun-21	16x	600436.CG	Pientzehuang Pharma	Pharma	Feb-16	Jan-21	10x
175.HK	Geely	Autos	Oct-08	Oct-10	15x	000893.CS	Asia-Potash Int'l	Materials	Jul-18	Apr-22	10x
002714.CS	Muyuan Foods	Food Bev	Jan-17	Feb-21	15x	600779.CG	Sichuan Swellfun	Food Bev	Sep-15	Aug-20	10x
300122.CS	Zhifei Biological Products	Pharma	Jan-17	Apr-21	15x	000155.CS	Sichuan New Energy Power	Cap Goods	Jan-19	Aug-21	10x
600132.CG	Chongqing Brewery	Food Bev	Jul-16	Jun-21	15x	600346.CG	Hengli Petrochemical	Materials	Jun-16	Jan-21	10x
384.HK	China Gas	Utilities	Oct-08	Jul-13	15x	PDD.UW	PDD	Retailing	Oct-18	Dec-20	10x

<sup>^</sup>based on current constituents; calculated by monthly date since 2000

Source: MSCI, FactSet, Goldman Sachs Global Investment Research

## All stars are aligned: Growing with Chinese “Little Giants”

**What are Chinese “Little Giants”?** Since 2018, the Ministry of Industry and Information Technology (MIIT) has selected more than 1mn SMEs and/or emerging companies concentrated in the Technology and Industrial sectors as strategic development focuses by 2025. Later on, the chosen companies were further categorized into four main tiers—Innovative SMEs, SRDI (Specialized, Refined, Differentiated, Innovative) SMEs, “Little Giants” and Niche Market Leaders—depending on their size, industry positioning, business maturity, and technological competitiveness. Among the four groups, the “Little Giants” cohort seems to have received the most attention from the authorities from both the media propaganda and actual policy implementation (e.g. specific measures at the Central and Provincial government levels) standpoints. Out of the full “Little Giants” universe with a total 9119 companies as of August 2022, 703 of them (or their parent companies/main subsidiaries) are listed in A shares based on the mapping from WIND, mostly hosted by the ChiNext and STAR boards.

### **Top down, listed “Little Giants” check many boxes that define the successful formula of historical multibaggers:**

- From a policy alignment perspective, **they are handpicked by the Chinese authorities for explicit and comprehensive policy support**, spanning administrative measures, easier access to capital markets, to tax incentives and direct subsidies.
- Sectorally, the listed “Little Giants” mainly reside in Cap Goods, (new) Materials, Tech Hardware, and Semi, all of which are **critical to Chinese national security**, growth sustainability, and supply chain stability, in our view.
- Thematically, they are well synced with, and are essential building blocs to, **the “Common Prosperity” vision** considering their sector exposures/composition according to our “Common Prosperity” framework.
- In terms of market attributes, the listed “Little Giants” carry a strong **small/mid-cap flavor** in the context of A shares, averaging Rmb7.6bn/US\$1.1bn of listed market cap, but with **a reasonably strong liquidity profile** of US\$16mn of ADT.
- Fundamentally, they realized 22% top-line and 21% of bottom-line growth in the past 2 years on a median basis, and are expected by Wind consensus to **generate 35% EPS CAGR** in the next 2 (2022-2024E) years vs. 21% by CSI300. Their historical profit growth track record may not appear as strong as their STAR and ChiNext peers, but they have similar profitability, ROE, and R&D statistics. They on average trade over 21x fP/E on Wind consensus earnings (15x for CSI300), but **look attractively priced** when their growth potential is taken into consideration, boasting a PEG ratio of merely 0.6x.

Exhibit 20: "Little Giants" are handpicked by Chinese authorities for policy support, and appear strategically important to China in terms of its growth sustainability and national security



4 Rounds  
9119 "Little Giants"

Announced by	Area	Policy Support	Period
MINISTRY OF FINANCE THE PEOPLE'S REPUBLIC OF CHINA	Fiscal	Subsidize <b>RMB 6mn</b> each (2mn each year) by national government; extra RMB 0.2-2mn by local government; Preferential <b>tax</b> policy (vary at local level): lower VAT, profit tax; tax deduction by R&D expenditure	Valid for 3 years (eligible for extension for 3 more years upon review)
STATE TAXATION ADMINISTRATION OF THE PEOPLE'S REPUBLIC OF CHINA	Financing	<b>Broaden financing channels</b> for SMEs, and prepare high-quality ones for <b>IPOs</b>	
MIIT 工信部	Resource Allocation	Leverage market mechanism to <b>allocate technology, human capital and data</b> to these "Little Giants"	
CHINA BANKING AND INSURANCE REGULATORY COMMISSION	Regulation	<b>Lower barriers to entry</b> by streamlining administrative and regulatory power	
中国人民银行 THE PEOPLE'S BANK OF CHINA	Digitalization	Implement special action plans to enhance SMEs' ability to use <b>digital and design</b> resources	
NRDC 发改委	Public Service	Support service agencies to develop service projects for innovative "Little Giant" enterprises, and conduct extensive management consulting and talent training	


Source: Wind, MoF, STA, MIIT, Data compiled by Goldman Sachs Global Investment Research

**Exhibit 21: Case studies: Policy support to Little Giants in Zhejiang and Guangdong**

	Zhejiang	Guangdong
<b>Fiscal</b>	An one-off extra reward of RMB 0.5-1mn	An one-off extra reward of RMB 2mn
<b>Financing</b>	The "Zheke Loan" provided Little Giant enterprises with an <b>increase of &gt;30%</b> on the mortgage-free guaranteed loan amount, an increase of the loan period for <b>&gt;1 year</b> , and with the <b>best loan interest rate</b>	Proportion of the "little giant" enterprises obtaining loans reached <b>74.3%</b> , <b>30% higher</b> than other enterprises
<b>Resource Allocation</b>	Talents in the Little Giant Enterprise can apply for the senior professional <b>titles</b> and will be provided supports in <b>housing</b> and children's <b>education</b>	Each "Little Giant" enterprise in Guangdong will own <b>2 quotas</b> for talents on an one-time <b>RMB 100,000</b> reward
<b>Digitalization</b>	Establish <b>pilot programs</b> for digital transformation. Each service platform should complete the digitalization for <b>&gt;10</b> pilot enterprises within <b>a year</b>	Guangzhou gives <b>30%</b> direct <b>subsidy</b> for the digital transformation costs of Little Giant enterprises
<b>Public Service</b>	<b>Zhejiang University</b> has set up a number of "Little Giant" talents cultivation and promotion projects	Guangzhou has spent >RMB 3 mn every year to purchase <b>professional consulting services</b> for enterprise development since 2020


Source: Government websites, Data compiled by Goldman Sachs Global Investment Research

**Exhibit 22: Media/policy emphasis on SRDI SMEs, notably "Little Giants", has been on a rise**



Note: based on People's Daily, China Daily and Xinhua.net


**Exhibit 23: Many "Little Giants" are listed on ChiNext, followed by the STAR Board**



Source: Wind, FactSet, Goldman Sachs Global Investment Research

**Exhibit 24: Sectorally, "Little Giants" are mainly concentrated in (New) Materials, Cap Goods, Hardware Tech, and Semi**


**Distribution of "Little Giants" by GICS II Industry Group**



Data label: Industry group name + # of "Little Giants" + market cap %

Source: Wind, FactSet, Goldman Sachs Global Investment Research

**Exhibit 25: Many "Little Giants" are small/mid caps and have relatively thin liquidity at the tail end**



Source: Wind, FactSet, Goldman Sachs Global Investment Research

**Exhibit 26: "Little Giants" are expected by WIND consensus to deliver similar profit growth as their ChiNext and STAR peers in the next 2 years**


**Fundamental Metric Comparison (based on median level of constituents)**

		"Little Giants"	STAR50	Chinext100	CSI300
# of stocks		703	50	100	300
Revenue growth (yoy)	2020	16%	31%	27%	14%
	2021	28%	51%	33%	24%
Earnings growth (yoy)	2020	26%	76%	37%	20%
	2021	16%	49%	35%	24%
	2022E	36%	42%	31%	12%
	2023E	38%	41%	30%	23%
	2024E	31%	33%	26%	19%
Capex growth (yoy)	2020	30%	41%	39%	15%
	2021	56%	94%	64%	26%
R&D Intensity	2020	5.6%	8.7%	6.0%	3.1%
	2021	5.7%	9.0%	6.0%	3.0%
Profit margin	2020	15%	17%	18%	15%
	2021	14%	18%	18%	16%
ROE	2020	11%	10%	14%	12%
	2021	10%	11%	15%	12%

*^Values higher than peers are highlighted in green; earnings growth estimates based on Wind consensus forecasts (median level of constituents with data available).*

Source: Wind, Goldman Sachs Global Investment Research

**Exhibit 27: "Little Giants" are trading on lower PE and PB relative to ChiNext and STAR stocks**



based on median level of constituents


Source: Wind



# Introducing GS “Little Giants” Portfolio (GSSRCNLG)


- While the “Little Giants” story seems compelling to us and could be a major source of potential alpha generation in the years to come, **it might not be a practical theme for some investors** given its broad universe (703 stocks, 57 sub-industries), small/mid cap bias, limited sell-side footprint, and other corporate governance concerns (e.g. accounting standards, ESG compliance).
- As such, we leverage **various top-down growth, valuation, and R&D parameters**, corporate-governance related considerations such as the breadth of **sell-side coverage** and **management incentive plans**, and accessibility factors (ADT and Northbound eligibility) to distill the broad theme into a more confined universe.
- The above conditions allow us to screen for **40 names (all Northbound Connect eligible) from 17 sub-industries and form our GS “Little Giant” Portfolio (GSSRCNLG)**, of which 13 are covered by our equity analysts. Sectorally, 85% of the basket weights are concentrated in Tech (Hardware), Materials, and Health Care. It has an aggregate/average market cap of US\$180bn/4.5bn and ADT of US\$2bn/61mn, trades on 25x fP/E and 0.8x fPEG, and is expected by IBES consensus to grow earnings by 36% CAGR over the next 2 years. While its absolute valuations look high, the portfolio is trading on all-time lows in fP/E and fPEG terms, both at -2.1 s.d. to their respective historical means.
- Our back-test shows that the basket has gained 115% since 2020, significantly outperforming CSI500, CSI300, and MSCI China by 109pp, 123pp, and 146pp respectively. It has demonstrated a beta of 1.1 to CSI500, but only 1.0 to CSI300/ChiNext and 0.8 to STAR, suggesting that it could be **an effective vehicle to buy Growth in China without taking excessive beta risk**.

**Exhibit 28: The constituents spread across 17 sub-industries, with a strong “Hard Tech” flavor**




Source: Wind, FactSet, Goldman Sachs Global Investment Research

**Exhibit 29: The basket has gained 115% since 2020, outperforming CSI500, CSI300 and MXCN by 109pp, 123pp and 146pp respectively**




Source: Wind, FactSet, Goldman Sachs Global Investment Research

**Exhibit 30: The basket is trading at historically low valuations in both PE and PEG terms**



Source: Wind, FactSet, Goldman Sachs Global Investment Research

**Exhibit 31: The basket has been less volatile compared with ChiNext and STAR**



Source: Wind, FactSet, Goldman Sachs Global Investment Research

**Exhibit 32: The constituents of our Little Giants Basket (GSSRCNLG)**

Ticker	Name	GICS Sub-Industry	Basket weight <sup>A</sup>	Top 50 (on avg %ile ranking)			Management incentive plans <sup>AA</sup>	Analyst coverage (IBES)	Listed Mkt Cap (US\$bn)	6M ADVT (US\$m)	23E PE (x)	22E PEG (x)	2022-24E EPS CAGR (%)
				R&D intensity (past 3y avg)	Revenue CAGR (2021-23E)	ROE (past 3y avg)							
<b>Common Prosperity Basket</b>													
002812 CS	Yunnan Energy New Material	Commodity Chemicals	5.0%	5%	51%	18%	√	28	21.9	188	22	0.7	39
002049 CS	Unigroup Guoxin Microelectronics	Semiconductors	5.0%	15%	32%	20%	√	16	17.3	191	30	1.1	35
603698 CS	Highspeed	Specialty Chemicals	5.0%	5%	51%	13%	√	17	10.9	99	18	0.7	36
688063 CG	Putaiai New Energy Technology	Specialty Chemicals	5.0%	7%	109%	11%	√	10	8.7	138	36	0.6	81
300142 CS	Pylon Technologies	Electrical Components & Equipment	5.0%	17%	35%	7%	√	6	8.2	142	32	0.9	37
603290 CG	StarPower Semiconductor	Semiconductors	5.0%	7%	48%	14%	√	22	7.8	116	53	2.1	36
603185 CG	Wuxi Shangji Automation	Industrial Machinery	4.9%	4%	81%	27%	√	4	7.4	188	10	0.2	42
002821 CS	Asymchem Laboratories	Pharmaceuticals	4.5%	8%	52%	16%	√	20	6.7	139	19	6.3	9
300661 CS	SG Micro	Semiconductors	4.5%	17%	41%	25%	√	21	6.7	77	35	1.4	32
300769 CS	Shenzhen Dynanonic Cons Disc	Commodity Chemicals	4.3%	5%	141%	26%	√	14	6.4	123	19	1.0	26
300699 CS	Weihai Guaswei Composites	Commodity Chemicals	4.0%	11%	17%	18%	√	12	6.1	56	35	1.7	24
688301 CG	Iray Technology	Health Care Equipment	3.6%	14%	28%	13%	√	8	5.3	26	45	1.6	32
300604 CS	Changchuan Technology	Semiconductor Equipment	3.2%	24%	58%	7%	√	7	4.9	65	44	1.3	45
002414 CS	Wuhan Guide Infrared	Electronic Equipment & Instruments	2.9%	15%	16%	17%	√	6	4.3	61	21	1.0	23
688598 CG	KBC Corp. Ltd. Class A	Commodity Chemicals	2.6%	8%	28%	22%	√	12	4.0	61	31	1.2	33
688188 CG	Shanghai Friendess Electronics	Electronic Equipment & Instruments	2.6%	13%	21%	17%	√	10	3.9	16	32	1.2	33
300357 CS	Wolvo Bio-Pharmaceutical	Pharmaceuticals	2.4%	11%	21%	22%	√	10	3.6	18	49	2.3	28
603127 CG	Joinn Laboratories	Life Sciences Tools & Services	2.4%	5%	33%	20%	√	15	3.6	51	29	1.3	30
300487 CS	Sunesin New Materials	Commodity Chemicals	2.3%	6%	46%	18%	√	4	3.4	30	34	1.2	29
688200 CG	Huafeng Test & Control Technology	Semiconductor Equipment	1.9%	13%	31%	14%	√	18	2.9	41	25	1.0	34
300777 CS	Sinofibers Technology	Commodity Chemicals	1.9%	9%	72%	18%	√	5	2.8	45	30	1.1	35
003031 CS	Hebei Sinopack Electronic Technology	Electronic Components	1.9%	13%	33%	10%	√	6	2.8	24	82	2.7	34
688019 CG	Anji Microelectronics Technology	Semiconductor Equipment	1.8%	21%	44%	13%	√	8	2.7	31	61	2.3	43
300775 CS	Xi'an Triangle Defense	Aerospace & Defense	1.7%	4%	36%	15%	√	5	2.5	41	21	0.8	35
300035 CS	Hunan Zhongke Electric	Industrial Machinery	1.4%	6%	85%	11%	√	8	2.2	82	13	0.3	56
688696 CG	Chengdu Xgimi Technology	Consumer Electronics	1.4%	5%	25%	34%	√	14	2.1	32	17	0.7	31
300613 CS	Fulhan Microelectronics	Semiconductors	1.2%	20%	34%	12%	√	7	1.8	43	18	0.7	29
300767 CS	QuakeSafe Technologies	Construction Materials	1.1%	3%	105%	11%	√	9	1.7	21	25	0.5	82
300841 CS	Kanghua Biological Products	Biotechnology	1.1%	5%	43%	28%	√	7	1.6	24	9	0.3	37
300567 CS	Wuhan Jingce Electronic	Electronic Equipment & Instruments	1.1%	16%	9%	14%	√	7	1.6	26	32	1.3	59
688016 CG	MicroPort Endovascular MedTech	Health Care Supplies	1.1%	17%	30%	20%	√	6	1.6	23	20	0.7	34
300638 CS	Fibocom Wireless, Inc.	Communications Equipment	1.1%	11%	33%	21%	√	13	1.6	20	15	0.6	28
300394 CS	Suzhou TFC Optical Communication	Communications Equipment	1.0%	10%	26%	18%	√	14	1.5	25	20	0.9	27
300653 CS	Yantai Zhenghai Bio-Tech	Biotechnology	0.9%	8%	23%	21%	√	4	1.4	19	33	1.2	42
300481 CS	Puyang Huicheng Electronic Material	Specialty Chemicals	0.9%	7%	21%	18%	√	6	1.4	45	21	1.2	23
002810 CS	Shandong Head Group	Commodity Chemicals	0.9%	4%	35%	22%	√	5	1.4	32	13	0.4	35
300811 CS	POCO Holding	Electronic Components	0.9%	6%	38%	13%	√	5	1.3	13	33	1.0	41
300401 CS	Zhejiang Garden Bio-chemical High-tech	Pharmaceuticals	0.9%	6%	34%	17%	√	4	1.3	33	13	0.5	34
300685 CS	Amoy Diagnostics	Biotechnology	0.9%	16%	18%	18%	√	7	1.3	12	24	1.6	24
603668 CG	Yijiahe Technology	Industrial Machinery	0.8%	13%	27%	22%	√	4	1.2	21	11	0.5	22
<b>Average</b>									4.5	61	28	1.2	36
<b>Aggregate</b>									180	2,435	24	0.6	34

Notes: Prices as of Sep 30, 2022; Valuation items are I/B/E/S consensus. Stocks that are not eligible for Northbound Stock Connect have been excluded. <sup>A</sup>Basket is market cap-weighted while weights of individual stocks are capped at 5%. <sup>AA</sup>√ indicates companies have conducted management incentive plans since 2016

Source: Wind, FactSet, IBES, Goldman Sachs Global Investment Research



## Appendix

Exhibit 33: Policy focuses are evolving in China as the economy grows, as exemplified by the four 5-Year Plans in the past 2 decades

	Time period	Major objective		Key targets		Realized GDP growth and unemployment rate
Tenth Five-Year Plan	2001–2005	To build a relatively complete social security system and make significant progress in establishing a modern enterprise system in state-owned enterprises.	Quantitative	- Average annual GDP growth at 7%	√	Realized annual GDP growth: 9.8% Realized registered urban unemployment rate: 4.2%
				- Registered urban unemployment rates at 5%	√	
				- Per capita disposable income of residents increase by 5% annually	√	
			Qualitative	- Raise R&D funding to 1.5% of GDP	X	
				- Optimize and upgrade the industrial structure		
				- Improve the national economy and social IT levels		
Eleventh Five-Year Plan	2006–2010	Optimize and upgrade the industrial structure and improve resource utilization.	Quantitative	- Average annual GDP growth at 7.5%	√	Realized annual GDP growth: 11.2% Realized registered urban unemployment rate: 4.1%
				- Urbanization rate up to 47% in 2010	√	
				- Registered urban unemployment rates at 5%	√	
			Qualitative	- Per capita disposable income of residents increase by 5% annually	√	
				- Raise R&D funding to 2% of GDP	X	
				- Quality growth with focus on "greener" GDP		
Twelfth Five-Year Plan	2011–2015	Increase input in education and science and technology and set goals for environmental protection.	Quantitative	- Average annual GDP growth at 7%	√	Realized annual GDP growth: 7.8% Realized registered urban unemployment rate: 4.1%
				- Urbanization rate increase by 4%	√	
				- Registered urban unemployment rates at 5%	√	
			Qualitative	- Per capita disposable income of residents increase by 7% annually	√	
				- Raise research and development funding to more than 2.2% of GDP	X	
				- Urbanization		
Thirteenth Five-Year Plan	2016–2020	Doubling income goal; Use innovation to drive development.	Quantitative	- Household income increases		Realized annual GDP growth: 6.7% (2019) Realized registered urban unemployment rate: 3.8%
				- Housing reform		
				- Income redistribution and public service provision		
			Qualitative	- Average annual GDP growth at 6.5%	X	
				- The value added of service increase to 56%	X	
				- Registered urban unemployment rates at 5%	√	
Fourteenth Five-Year Plan	2021–2025	Strengthen the domestic circulation; Make progress on the common prosperity	Quantitative	- Technological progress contribute to >60% of economic growth	√	-
				- Raise research and development funding to more than 2.5% of GDP	X	
				- Encourage people to do business creatively and drive innovation		
			Qualitative	- Made in China 2025		
				- Economy needs a Rule of Law"		
				- National defense reform		

Note: Target data that is not available for fourteenth five-year plan is marked with "X".

Source: Xinhua.net, Reuters, Data compiled by Goldman Sachs Global Investment Research

Exhibit 34: 134 names in the existing MSCI China universe have returned more than 10x within any 5-year periods over the past 20 years

Table with columns: Ticker, Name, Industry Group, 2000-present, Start-end, US\$mm, x, x, x, x, US\$mm, USDmm, x, x, x, x, US\$mm, Start-end, SP5 CAGR, EPS CAGR, Favorable review rate, Policy tailwinds. Rows list 134 companies like 9125.MF, 1268.HK, 2333.HK, etc.

\*Based on current MSCI constituents, calculated by monthly data since 2000, \*\*2021Y net income is used when end date is in 2022, attributes that meet the criteria are highlighted with green circles

Source: MSCI, FactSet, Goldman Sachs Global Investment Research

Exhibit 35: Distribution of multi-baggers by starting year & sector

Starting Year		2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Total	
Cyclicals	Capital Goods	-	-	-	-	-	2	1	-	1	-	-	-	-	-	-	-	3	-	4	2	1	14	
	Transportation	-	-	3	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4
	Autos & Components	1	-	-	-	-	1	-	-	-	2	-	-	-	-	-	-	-	1	-	3	1	-	9
	Consumer Durables	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	2	1	-	-	1	5
	Consumer Services	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	-	-	-	-	-	2
	Commercial Services	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
	Retailing	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	3	-	1	-	-	5
	Software & Services	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	-	-	3
	Media & Entertainment	-	1	-	-	-	1	1	-	-	1	-	-	-	-	-	-	1	-	-	1	-	1	7
	Tech Hardware	-	-	1	-	-	-	-	-	-	1	-	-	1	1	-	-	-	-	-	-	1	-	5
Semiconductors	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	4	4	-	-	10	
Comm - odities	Energy	1	-	2	2	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	6	
	Materials	-	-	3	-	1	-	1	-	3	-	-	-	-	-	-	-	-	3	2	5	1	-	19
Financials	Banks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	
	Diversified Financials	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	
	Insurance	-	-	-	-	2	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	
	Real Estate	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	1	-	1	-	-	1	-	6
Defensives	Telecom	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	
	Food & Beverage	1	-	-	-	-	1	-	-	1	-	-	-	-	-	-	1	3	3	2	-	-	12	
	Pharma & Biotech	1	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	3	4	1	1	-	11	
	Utilities	1	-	2	-	-	-	1	-	2	-	-	-	-	-	-	-	-	-	-	-	-	6	
	Health Care Equip & Svcs	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	1	3	-	-	5	
	Household Products	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
<b>Total</b>		<b>6</b>	<b>1</b>	<b>13</b>	<b>5</b>	<b>3</b>	<b>8</b>	<b>4</b>	<b>0</b>	<b>12</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>24</b>	<b>18</b>	<b>22</b>	<b>7</b>	<b>2</b>	<b>134</b>	

Source: MSCI, FactSet, Goldman Sachs Global Investment Research

Exhibit 36: Distribution of multi-baggers by ending year & sector

Ending Year		2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	Total
Cyclicals	Capital Goods	-	-	-	-	-	-	-	-	1	2	-	-	1	-	-	-	-	-	-	1	9	-	14
	Transportation	-	-	-	-	-	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4
	Autos & Components	-	-	-	1	-	-	-	-	-	2	-	-	1	-	-	-	-	-	-	-	4	1	9
	Consumer Durables	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	4	-	5
	Consumer Services	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	-	-	-	2
	Commercial Services	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
	Retailing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	3	1	-	5
	Software & Services	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	-	3
	Media & Entertainment	-	-	-	-	-	1	-	-	1	-	1	-	-	1	-	-	-	1	-	-	2	-	7
	Tech Hardware	-	-	-	-	-	1	-	-	-	-	-	-	1	-	-	1	1	-	-	-	-	1	5
Semiconductors	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	8	1	10
Comm - odities	Energy	-	-	-	-	1	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	6
	Materials	-	-	-	-	-	5	-	1	-	2	-	-	-	-	-	-	-	-	-	-	10	1	19
Financials	Banks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	
	Diversified Financials	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	
	Insurance	-	-	-	-	-	2	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	3	
	Real Estate	-	-	-	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	1	6
Defensives	Telecom	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	
	Food & Beverage	-	-	1	-	-	-	-	1	-	1	-	-	-	-	-	-	-	-	-	3	6	-	12
	Pharma & Biotech	-	-	-	-	1	-	-	-	-	-	-	-	1	-	-	-	-	-	-	1	8	-	11
	Utilities	-	-	-	1	-	-	2	1	-	-	-	-	2	-	-	-	-	-	-	-	-	-	6
	Health Care Equip & Svcs	-	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	4	-	5
	Household Products	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
<b>Total</b>		<b>1</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>23</b>	<b>1</b>	<b>5</b>	<b>5</b>	<b>4</b>	<b>0</b>	<b>7</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>11</b>	<b>59</b>	<b>4</b>	<b>134</b>

Source: MSCI, FactSet, Goldman Sachs Global Investment Research



# Disclosure Appendix

## Reg AC

We, Kinger Lau, CFA, Timothy Moe, CFA, Kevin Wang, CFA and Si Fu, Ph.D., hereby certify that all of the views expressed in this report accurately reflect our personal views, which have not been influenced by considerations of the firm's business or client relationships.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

## Disclosures

### Basket Disclosure

The ability to trade the basket(s) in this report will depend upon market conditions, including liquidity and borrow constraints at the time of trade.

## Regulatory disclosures

### Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage.

**Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

### Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of the Global Investment Research Division of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

**European Union and United Kingdom:** Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is

implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

**Japan:** Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan and Type II Financial Instruments Firms Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

## Global product; distributing entities

The Global Investment Research Division of Goldman Sachs produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or [contatogoldmanbrasil@gs.com](mailto:contatogoldmanbrasil@gs.com). Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou [contatogoldmanbrasil@gs.com](mailto:contatogoldmanbrasil@gs.com). Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Effective from the date of the United Kingdom's departure from the European Union and the European Economic Area ("Brexit Day") the following information with respect to distributing entities will apply:

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

**European Economic Area:** GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland, the Republic of Cyprus and the Republic of Ireland; GS - Succursale de Paris (Paris branch) which, from Brexit Day, will be authorised by the French Autorité de contrôle prudentiel et de résolution ("ACPR") and regulated by the Autorité de contrôle prudentiel et de résolution and the Autorité des marchés financiers ("AMF") disseminates research in France; GSI - Sucursal en España (Madrid branch) authorized in Spain by the Comisión Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSa as a "third country branch" in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sw. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom of Denmark; GSBE - Sucursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Succursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa "Consob") disseminates research in Italy; GSBE - Succursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfilial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinspektionen) disseminates research in the Kingdom of Sweden.

## General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by our Global Investment Research Division. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is focused on investment themes across markets, industries and sectors. It does not attempt to distinguish between the prospects or performance of, or provide analysis of, individual companies within any industry or sector we describe.

Any trading recommendation in this research relating to an equity or credit security or securities within an industry or sector is reflective of the investment theme being discussed and is not a recommendation of any such security in isolation.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if

appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and [https://www.fiadocumentation.org/fia/regulatory-disclosures\\_1/fia-uniform-futures-and-options-on-futures-risk-disclosures-booklet-pdf-version-2018](https://www.fiadocumentation.org/fia/regulatory-disclosures_1/fia-uniform-futures-and-options-on-futures-risk-disclosures-booklet-pdf-version-2018). Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

**Differing Levels of Service provided by Global Investment Research:** The level and types of services provided to you by the Global Investment Research division of GS may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2022 Goldman Sachs.

**No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of The Goldman Sachs Group, Inc.**